Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PsychoGenics and Dainippon Sumitomo Pharma have entered into a drug discovery agreement to screen selected Dainippon Sumitomo Pharma compounds in PsychoGenics's proprietary Drug Discovery Systems, with the aim of identifying new therapies for CNS disorders.
Subscribe to our email newsletter
Dainippon Sumitomo Pharma has a large product portfolio in the CNS area and has adopted a multifaceted research approach to target better treatments for psychiatric conditions, including schizophrenia, depression, anxiety and cognitive disorders. Dainippon Sumitomo Pharma is endeavoring to increase the number of early-stage CNS research projects by promoting early-stage research, and forming alliances with domestic and overseas research institutions, including universities and biotech companies with promising technologies.
Emer Leahy, president and CEO of PsychoGenics, said: “By combining Dainippon Sumitomo’s and PsychoGenics’s complementary strengths and expertise we are confident we will be able to identify treatments for neuropsychiatric disorders.”